ClinicalTrials.gg
CompletedNCT02459665VMBUpdated Jul 16, 2019Results posted

Rwanda Vaginal Microbiota Restoration Study

An interventional study of Vaginal multiple lactobacilli-containing probiotic for prevention of BV recurrence and Prophylactic use of metronidazole pills (500 mg) in Bacterial Vaginosis, sponsored by Janneke van de Wijgert. Completed. Open to female participants aged 18 Years to 45 Years. Per ClinicalTrials.gov, last updated 2019-07-16.

Sponsored by Janneke van de Wijgert · Not applicable, Interventional, and Prevention

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
68
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
Female
01

Study summary

A pilot randomized controlled clinical trial of intermittent use of two different vaginal lactobacilli-containing probiotics, and oral metronidazole, to prevent bacterial vaginosis recurrence.

Read the detailed description

This is a pilot study to prepare for larger clinical trials. Sixty-eight HIV-negative, non-pregnant, sexually active women aged 18-45 with bacterial vaginosis (BV, by modified Amsel criteria and/or Nugent score) and/or Trichomonas vaginalis (TV, on wet mount or by culture) will be treated using oral metronidazole for 7 days. After successful treatment, and when they are free of vaginal candidiasis, other curable sexually transmitted infections (STIs) and urinary tract infection (UTI)), they will be randomised to 4 different vaginal microbiome (VMB) maintenance interventions (17 per group) within 3 days of completing oral metronidazole treatment: 1) Behavioral 'vaginal practices cessation and safer sex' counselling only (control); 2) Behavioral counselling plus 500mg metronidazole pills twice per week for two months; 3) Behavioral counselling plus Ecologic Femi vaginal capsule, once per day for 5 days immediately after oral metronidazole treatment followed by thrice weekly, for two months; 4) Group 4: Behavioral counselling plus Gynophilus vaginal tablet, once every 4 days for two months. Vaginal probiotic use may be ceased temporarily during menstruation. Participants will be asked to adhere to the interventions for 2 months, and VMB assessments will take place before (screening and enrolment visits), during (Day 7, Month 1 and Month 2 visits), and after the interventions (Month 6 visit).

02

Conditions studied

  • Bacterial Vaginosis

Browse trials for

03

In context

Vaginosis, Bacterial

240 studies on the registry are indexed under Vaginosis, Bacterial; 39 are open to participants now.

This study's enrollment of 68 is below the median of 100 across 203 interventional studies indexed under Vaginosis, Bacterial.

Browse Vaginosis, Bacterial studies →

Lead sponsor

Janneke van de Wijgert is the lead sponsor of 3 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Sexually active, defined as having had sex at least twice in the two weeks prior to screening
  • At high risk of /STIs/BV, defined as having had more than one sexual partner in the last 12 months OR having been treated for an STI and/or BV in the last 12 months
  • Successfully treated for BV (modified Amsel criteria) or TV (wet mount), and free of STIs, symptomatic vaginal candidiasis and UTI at enrollment
  • Currently in good physical and mental health as judged by a study physician
  • Willing and able to adhere to study procedures and provide written .

Exclusion criteria

Exclusion Criteria:

  • Pregnant
  • positive
  • Clinician-observed genital ulcers, condylomata, or other genital abnormalities at screening or enrollment
  • Underwent a gynaecological surgery/invasive procedure in the 3 months prior to screening
  • History of significant urogenital prolapse, undiagnosed vaginal bleeding, urine or faecal incontinence, or blood clotting disorders
  • Allergic to metronidazole or any other components of the study drugs
  • Not willing to stop use of other oral or vaginal probiotics from the screening visit until the end of study participation
  • Participating in another health intervention study
  • For any other reason potentially interfering with participant safety or protocol adherence as judged by the Principal Investigator
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
68 participants (actual)

Study arms

  • No intervention
    Group 1

    Negative control group: After initial treatment for BV/TV, no intervention.

  • Other
    Group 2

    Positive control group: After initial treatment for BV/TV, metronidazole pills (500 mg) twice per week for 2 months.

    Drug: Prophylactic use of metronidazole pills (500 mg)

  • Active comparator
    Group 3

    After initial treatment for BV/TV, Ecologic Femi+ vaginal capsule (a vaginal probiotic) once per day for 5 days immediately after the initial treatment followed by thrice weekly for two months.

    Biological: Vaginal multiple lactobacilli-containing probiotic for prevention of BV recurrence

  • Active comparator
    Group 4

    After initial treatment for BV/TV, Gynophilus LP vaginal tablet (a vaginal probiotic) once every 4 days for two months.

    Biological: Vaginal Lcr35-containing probiotic for prevention of BV recurrence

Interventions

  • BiologicalVaginal multiple lactobacilli-containing probiotic for prevention of BV recurrence

    Vaginal probiotic to restore the vaginal microbiome and prevent BV recurrence after metronidazole treatment for BV or TV

    Also known as: Ecologic Femi+ vaginal capsule

  • DrugProphylactic use of metronidazole pills (500 mg)

    Prophylactic use of metronidazole pills to prevent BV recurrence after metronidazole treatment for BV or TV

    Also known as: Tricozole

  • BiologicalVaginal Lcr35-containing probiotic for prevention of BV recurrence

    Vaginal probiotic to restore the vaginal microbiome and prevent BV recurrence after metronidazole treatment for BV or TV

    Also known as: Gynophilus LP vaginal tablet

06

What researchers measure

Primary outcomes

  1. Bacterial Vaginosis (BV) Incidence by Modified Amsel Criteria

    Modified Amsel criteria positive is at least 2 of 3 of the following positive: clue cells, vaginal pH, whiff test. Modified intent-to-treat (ITT) analyses (women with Nugent 7-10 at enrollment excluded), using person-years (PY) at risk as denominator of each incidence rate.

    Time frame: 2 months (intervention period)

  2. Bacterial Vaginosis (BV) Incidence by Nugent Scoring (Nugent 7-10)

    The Nugent score is a scale from 0-10 based on visualisation of three different bacterial morphotypes on a Gram stained slide, but in the incidence rates, the variable was used as a binary variable: BV present (Nugent score 7-10) or absent (Nugent score 0-6). Modified intent-to-treat (ITT) analyses (women with Nugent 7-10 at enrollment excluded), using person-years (PY) at risk as the denominator for each incidence rate.

    Time frame: 2 months (intervention period)

  3. Trichomonas Vaginalis (TV) Incidence by Culture

    A swab was inoculated into an InPouch culture pouch, specifically designed for TV growth. The pouch was checked daily for five days to detect growth. The results was positive when growth detected and negative when no growth detected on the fifth day. Intent-to-treat (ITT) analyses, using person-years (PY) at risk as the denominator for each incidence rate.

    Time frame: 2 months (intervention period)

  4. Vaginal Candidiasis Incidence by Wet Mount Microscopy

    A wet mount is a smear of vaginal fluid on a microscopy slide, which is examined under a microscope. Yeasts are visible without staining. The definition of vaginal candidiasis was any yeast visible on the wet mount. Symptomatic vaginal candidiasis was considered a safety outcome because treatment of bacterial vaginosis often results in vaginal candidiasis. Intent-to-treat (ITT) analysis with person-years (PY) at risk as the denominator of all incidence rates.

    Time frame: 6 months: 2 months intervention period plus 4 months after intervention cessation

Secondary outcomes

  1. Vaginal Microbiota Composition by Illumina HiSeq Sequencing: Lactobacillus Genus Concentration

    The vaginal microbiota sequencing results are exploratory and full data can be found in a manuscript on the BioRxiv preprint server. The most important outcome is the concentration of Lactobacillus genus in vaginal samples taken at the end of the intervention period (M2 visit).

    Time frame: 2 months (intervention period)

Other outcomes

  1. Feasibility/Acceptability of Vaginal Probiotic Use by Structured Face-to-face Interview

    Full results have been submitted for publication. Adherence was measured at D7, M1, and M2 visits, and a summary measure over the entire period was calculated (available for women using oral metronidazole, Ecologic Femi+, or Gynophilus LP). After the 2-month intervention period, women using vaginal probiotics (Ecologic Femi+ or Gynophilus LP) were asked structured questions about their experiences with product use.

    Time frame: 2 months (intervention period)

07

Results

Posted Jul 16, 2019
Limitations and caveats
The two most important limitations were the modest sample size (this trial was funded as a pilot trial) and our inability to exclude women with gonorrhea and/or chlamydia infection at the time of randomization (due to slow testing turn-around).

Participant flow

The target population was women at high risk of urogenital infections living in Kigali, Rwanda. Recruitment activities were implemented by study staff with the help of Community Mobilizers, who were selected due to their strong connections with high-risk women in Kigali. They helped staff organize recruitment meetings in relevant communities.

Participant flow — Overall Study
MilestoneControlOral MetronidazoleEcologic Femi+Gynophilus LP
Started17171717
Day 7 visit17171716
Month 1 visit17171716
Month 2 visit17161716
Month 6 visit17161615
Completed17161615
Not completed0112
Withdrew: Withdrawal by subject0112

Outcome measures

PrimaryBacterial Vaginosis (BV) Incidence by Modified Amsel Criteria

Modified Amsel criteria positive is at least 2 of 3 of the following positive: clue cells, vaginal pH, whiff test. Modified intent-to-treat (ITT) analyses (women with Nugent 7-10 at enrollment excluded), using person-years (PY) at risk as denominator of each incidence rate.

Time frame:
2 months (intervention period)
Reported as:
Number · Incidence: events per PY at risk
Bacterial Vaginosis (BV) Incidence by Modified Amsel Criteria
Incidence: events per PY at riskControlOral MetronidazoleEcologic Femi+Gynophilus LP
Bacterial Vaginosis (BV) Incidence by Modified Amsel Criteria7.53 (4.28 to 13.26)2.04 (0.66 to 6.31)3.36 (1.51 to 7.48)3.35 (1.26 to 8.92)
PrimaryBacterial Vaginosis (BV) Incidence by Nugent Scoring (Nugent 7-10)

The Nugent score is a scale from 0-10 based on visualisation of three different bacterial morphotypes on a Gram stained slide, but in the incidence rates, the variable was used as a binary variable: BV present (Nugent score 7-10) or absent (Nugent score 0-6). Modified intent-to-treat (ITT) analyses (women with Nugent 7-10 at enrollment excluded), using person-years (PY) at risk as the denominator for each incidence rate.

Time frame:
2 months (intervention period)
Reported as:
Number · Incidence: events per PY at risk
Bacterial Vaginosis (BV) Incidence by Nugent Scoring (Nugent 7-10)
Incidence: events per PY at riskControlOral MetronidazoleEcologic Femi+Gynophilus LP
Bacterial Vaginosis (BV) Incidence by Nugent Scoring (Nugent 7-10)10.18 (5.48 to 18.92)1.41 (0.35 to 5.62)3.58 (1.61 to 7.96)5.36 (2.41 to 11.93)
PrimaryTrichomonas Vaginalis (TV) Incidence by Culture

A swab was inoculated into an InPouch culture pouch, specifically designed for TV growth. The pouch was checked daily for five days to detect growth. The results was positive when growth detected and negative when no growth detected on the fifth day. Intent-to-treat (ITT) analyses, using person-years (PY) at risk as the denominator for each incidence rate.

Time frame:
2 months (intervention period)
Reported as:
Number · Incidence: events per PY at risk
Trichomonas Vaginalis (TV) Incidence by Culture
Incidence: events per PY at riskControl ArmMetronidazole ArmEcologic Femi+ ArmGynophilus LP Arm
Trichomonas Vaginalis (TV) Incidence by Culture1.10 (0.35 to 3.41)0 (0 to 0)0 (0 to 0)0 (0 to 0)
PrimaryVaginal Candidiasis Incidence by Wet Mount Microscopy

A wet mount is a smear of vaginal fluid on a microscopy slide, which is examined under a microscope. Yeasts are visible without staining. The definition of vaginal candidiasis was any yeast visible on the wet mount. Symptomatic vaginal candidiasis was considered a safety outcome because treatment of bacterial vaginosis often results in vaginal candidiasis. Intent-to-treat (ITT) analysis with person-years (PY) at risk as the denominator of all incidence rates.

Time frame:
6 months: 2 months intervention period plus 4 months after intervention cessation
Reported as:
Number · Incidence: events per PY at risk
Vaginal Candidiasis Incidence by Wet Mount Microscopy
Incidence: events per PY at riskControlOral MetronidazoleEcologic Femi+Gynophilus LP
Vaginal Candidiasis Incidence by Wet Mount Microscopy0 (0 to 0)0 (0 to 0)0 (0 to 0)0 (0 to 0)
SecondaryVaginal Microbiota Composition by Illumina HiSeq Sequencing: Lactobacillus Genus Concentration

The vaginal microbiota sequencing results are exploratory and full data can be found in a manuscript on the BioRxiv preprint server. The most important outcome is the concentration of Lactobacillus genus in vaginal samples taken at the end of the intervention period (M2 visit).

Time frame:
2 months (intervention period)
Reported as:
Mean · Lactobacillus log10 copies/microliter
Vaginal Microbiota Composition by Illumina HiSeq Sequencing: Lactobacillus Genus Concentration
Lactobacillus log10 copies/microliterControlOral MetronidazoleEcologic Femi+Gynophilus LP
Vaginal Microbiota Composition by Illumina HiSeq Sequencing: Lactobacillus Genus Concentration3.86 (2.53 to 5.19)5.21 (4.27 to 6.14)5.30 (4.97 to 5.63)4.68 (3.55 to 5.81)
Other pre-specifiedFeasibility/Acceptability of Vaginal Probiotic Use by Structured Face-to-face Interview

Full results have been submitted for publication. Adherence was measured at D7, M1, and M2 visits, and a summary measure over the entire period was calculated (available for women using oral metronidazole, Ecologic Femi+, or Gynophilus LP). After the 2-month intervention period, women using vaginal probiotics (Ecologic Femi+ or Gynophilus LP) were asked structured questions about their experiences with product use.

Time frame:
2 months (intervention period)
Reported as:
Count of participants · Participants
Feasibility/Acceptability of Vaginal Probiotic Use by Structured Face-to-face Interview
ParticipantsOral MetronidazoleEcologic Femi+Gynophilus LP
Perfect (100%) overall adherence12108
Overall adherence ≥90%141511
Overall adherence ≥80%151713
Probiotic insertion as "very comfortable"—1715
Probiotic insertion became easier over time—1715

Adverse events

Collected over 6 months: during the 2-month intervention period and up to 4 months after intervention cessation. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Control0/17 (0%)0/17 (0%)2/17 (11.8%)
Oral Metronidazole0/17 (0%)1/17 (5.9%)2/17 (11.8%)
Ecologic Femi+0/17 (0%)1/17 (5.9%)2/17 (11.8%)
Gynophilus LP0/17 (0%)0/17 (0%)3/17 (17.6%)
Most frequent serious events
Most frequent serious events
EventControlOral MetronidazoleEcologic Femi+Gynophilus LP
Typhoid feverInfections and infestations0/171/170/170/17
Malaria during pregnancyInfections and infestations0/170/171/170/17
Most frequent other events
Most frequent other events
EventControlOral MetronidazoleEcologic Femi+Gynophilus LP
Genital burningReproductive system and breast disorders0/170/171/172/17
Genital itchingReproductive system and breast disorders2/172/172/172/17
Pain during sexReproductive system and breast disorders1/172/170/171/17
Burning when passing urineRenal and urinary disorders0/170/170/171/17
Lower abdominal painGeneral disorders0/170/170/171/17
Unusual vaginal dischargeReproductive system and breast disorders1/170/170/170/17
Sores in the genital and/or anal areaReproductive system and breast disorders0/170/170/171/17

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)ControlOral MetronidazoleEcologic Femi+Gynophilus LPTotal
<=18 years00000
Between 18 and 65 years1717171768
>=65 years00000
Age, Continuous
Age, Continuous(years)ControlOral MetronidazoleEcologic Femi+Gynophilus LPTotal
Median29 (24 to 36)30 (27 to 34)33 (28 to 35)31 (27 to 35)31 (27 to 35)
Sex: Female, Male
Sex: Female, Male(Participants)ControlOral MetronidazoleEcologic Femi+Gynophilus LPTotal
Female1717171768
Male00000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)ControlOral MetronidazoleEcologic Femi+Gynophilus LPTotal
African (Rwandan)1717171768
Region of Enrollment
Region of Enrollment(Participants)ControlOral MetronidazoleEcologic Femi+Gynophilus LPTotal
Rwanda1717171768
Exchanged sex for money/goods in past month
Exchanged sex for money/goods in past month(Participants)ControlOral MetronidazoleEcologic Femi+Gynophilus LPTotal
Count of participants1714151763
Sex partners in the past month
Sex partners in the past month(sex partners)ControlOral MetronidazoleEcologic Femi+Gynophilus LPTotal
Median5 (3 to 20)5 (2 to 10)3 (2 to 15)3 (2 to 20)5 (2 to 18)
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Verwijs MC, Agaba S, Umulisa MM, van de Wijgert JHHM. Feasibility and acceptability of frequent vaginal self-sampling at home by Rwandan women at high risk of urogenital tract infections. Sex Transm Infect. 2022 Feb;98(1):58-61. doi: 10.1136/sextrans-2020-054816. Epub 2021 Jan 29. PubMed 33514681 ↗
  • Verwijs MC, Agaba S, Umulisa MM, Uwineza M, Nivoliez A, Lievens E, van de Wijgert JHHM. Vaginal probiotic adherence and acceptability in Rwandan women with high sexual risk participating in a pilot randomised controlled trial: a mixed-methods approach. BMJ Open. 2020 May 19;10(5):e031819. doi: 10.1136/bmjopen-2019-031819. PubMed 32434932 ↗
  • Verwijs MC, Agaba SK, Darby AC, van de Wijgert JHHM. Impact of oral metronidazole treatment on the vaginal microbiota and correlates of treatment failure. Am J Obstet Gynecol. 2020 Feb;222(2):157.e1-157.e13. doi: 10.1016/j.ajog.2019.08.008. Epub 2019 Aug 9. PubMed 31404542 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2015 to primary completion in Feb 2016, 8 months.

Results were first posted in Jul 2019, 3 years 4 months after primary completion.

Of 52 interventional studies with no phase under Vaginosis, Bacterial, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 56. This study's 8 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
May 21, 2015
First posted
Jun 2, 2015
StartActual
Jun 5, 2015
Primary completionActual
Feb 23, 2016
CompletionActual
Aug 6, 2018
Results first posted
Jul 16, 2019
Last update
Jul 16, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 16, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02459665
Lead sponsor
Janneke van de Wijgert
Collaborators
Rinda Ubuzima, Rwanda
Responsible party
Janneke van de Wijgert (Professor of Infection and Global Health, University of Liverpool) — Sponsor-investigator
First posted
Jun 2, 2015
Start date
Jun 5, 2015
Primary completion
Feb 23, 2016
Completion
Aug 6, 2018
Results posted
Jul 16, 2019
Last update
Jul 16, 2019

Study contacts

Janneke H van de Wijgert, PhD
study chair · University of Liverpool

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion